key: cord-0778214-jveiiei1
authors: Bingöl Kızıltunç, Pınar; Seven, Mehmet Yunus; Atilla, Huban
title: Diplopia due to acquired Brown syndrome after COVID-19 infection
date: 2021-07-24
journal: J AAPOS
DOI: 10.1016/j.jaapos.2021.07.001
sha: ef76adca939bfe52fc450fd23c939429af44b2c4
doc_id: 778214
cord_uid: jveiiei1

Coronavirus disease 2019 (COVID-19) is a multisystem, inflammatory condition usually presenting with respiratory symptoms, such as fever, shortness of breath, and severe cough. It may also present with ocular, neurological, and musculoskeletal manifestations. However, since the emergence of the disease in 2019, only a few cases with ocular involvement have been reported in the literature. We present a case of acquired Brown syndrome secondary to COVID-19.

presenting with respiratory symptoms, such as fever, shortness of breath, and severe cough. It may also present with ocular, neurological, and musculoskeletal manifestations.

However, since the emergence of the disease in 2019, only a few cases with ocular involvement have been reported in the literature. We present a case of acquired Brown syndrome secondary to COVID-19.

A 31-year-old woman, an intensive care unit nurse, was admitted to the ophthalmology service, Ankara University, School of Medicine, with a complaint of double vision and pain in up-andleft gaze for 4 days. No history of systemic or ocular disease was noted other than dyschromatopsia. However, 3 weeks prior to admission, she tested positive for COVID-19 on real-time polymerase chain reaction testing. Complete blood count analysis showed a white blood cell count of 3340/mm 3 , indicating leukopenia. Laboratory blood analysis revealed that ferritin, fibrinogen, D-dimer, erythrocyte sedimentation rate, and C-reactive protein levels were within normal limits. The patient received combined treatment of favipiravir, enoxaparine, and dexamethasone as a standardized therapy for COVID-19. Prior to admission, however, only acetylsalicylic acid (81 mg/day) had been given to the patient. 

Ocular motility disorders associated with oculomotor nerve dysfunction in patients with COVID-19 have been reported previously. 2, 3 We present a case of myositis/trochleitis that manifested with diplopia and limited elevation in adduction, consistent with a Brown syndrome secondary to COVID-19.

COVID-19 is known to affect muscles, tendons, and cartilage, and cases of myositis involving paraspinal, facial, bulbar, proximal limb, and obturator muscles caused by SARS-CoV-2 have been reported. [4] [5] [6] In addition, arthritis, enthesitis, and dactylitis associated with SARS-CoV-2 infection have also been reported. 7, 8 The exact mechanism of musculoskeletal system involvement in patients with COVID-19 remains unclear, however. Various viral J o u r n a l P r e -p r o o f pathogens, such as hepatitis C, human immunodeficiency virus, Middle East respiratory syndrome coronavirus, and influenza A and B are known to cause myositis. Furthermore, SARS-CoV-2 has a high affinity for angiotensin-converting enzyme 2 (ACE2), which skeletal muscles express. 9 Thus, direct viral invasion of skeletal muscles by SARS-CoV-2 is possible.

Another mechanism of musculoskeletal system involvement may be the immunemediated pathway. Viral pathogens are known to cause immune-mediated myositis by triggering or exacerbating autoimmunity. 10 In addition, many inflammatory cells are stimulated, and cytokines are released in patients with COVID-19. This inflammatory response may trigger immune-mediated pathways or may be myotoxic.

In the present case, acquired Brown syndrome was associated with trochlear tendon complex involvement because orbital MRI revealed thickening and enhancement in the distal part of the superior oblique muscle-tendon-trochlea complex. In addition, the onset of ocular findings 3 weeks after COVID-19 infection suggests that this condition may be a reactive response rather than a direct viral invasion.

J o u r n a l P r e -p r o o f

The ocular motor examination

Acute abducens nerve palsy in a patient with the novel coronavirus disease (COVID-19)

Cranial nerve III palsy in the setting of COVID 19 infection. Epub ahead of print

Myositis as a manifestation of SARS-CoV-2. Epub ahead of print

COVID-19-associated myositis with severe proximal and bulbar weakness

Paraspinal Myositis in Patients with COVID-19 Infection

Can SARS-CoV-2 trigger reactive